Clinical Trial Update: MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009) [Phase 1]

View source ↗

Summary

A Phase 1 biomarker study of MK-8237 (SCH900237) in participants with allergic rhinitis or rhinoconjunctivitis has completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Allergic Rhinoconjunctivitis

Drugs mentioned

• MK-8237 (SCH900237) (MK-8237)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 1 | Status: COMPLETED | Results posted: 2017-02-13